About Us
INVESTMENT
FOCUS
Modi Ventures sits at the center of the venture ecosystem. We invest in both funds and founders, providing a unique perspective on the venture market and the tech bio sector. This includes a view of the capital fundraising environment, startup trends and hype cycles. Our focus on the intersection of technology and biology is rooted in our deep expertise and network in academia / labs, health / medicine, and frontier technologies such as artificial intelligence, multiomics and gene editing.
team
Sahir Ali is a highly accomplished technology and healthcare leader, investor, and board advisor with extensive experience in Artificial Intelligence, medical imaging, cancer research, enterprise technology, and cloud computing. He has advised and led some of the world's largest companies and organizations in implementing and integrating cutting-edge technologies and data science practices.
Amir Ali is an accomplished entrepreneur and venture capitalist with a strong background in Engineering and Technology. He serves as a Senior Partner at Modi Ventures, where he evaluates investment opportunities and mentors entrepreneurs. Additionally, he plays a pivotal role as the Principal at Modi Family Office, overseeing the family's business interests and investments with a focus on long-term growth and sustainability.
Ben Rosenbluth is a PhD candidate in Bioengineering at Stanford with expertise in protein engineering, genome editing, and drug delivery. He joined Modi Ventures in 2023, where he invests primarily in therapeutics. Prior to Modi, Ben co-founded Detect, one of three companies to receive FDA authorization for an over-the-counter COVID-19 molecular test, which sold hundreds of thousands of units and raised over $110M in funding. Before Detect, he co-founded a gene editing company developing full-length gene insertion tools to treat monogenic liver diseases, and previously worked as a Scientist at Quantum-Si developing single-molecule sequencing technologies. Ben has advised early-stage biotech companies and venture funds in technical and strategic roles, and brings company-building experience across therapeutics, diagnostics, and enabling platforms. He received his B.S. in Engineering Sciences from Yale University.
Kiley Giebel focuses on the intersection of Techbio and AI at Modi Ventures as an associate. She is also the Operations Manager at the Founder Mental Health Pledge, the largest global movement empowering entrepreneurs to prioritize their mental health and wellbeing.
J.D. Swartz is a seasoned marketing leader with expertise in brand strategy, digital experiences, creative management, and integrated marketing. Known for creating differentiated customer experiences that drive business value, J.D. excels in team building and delivering full-funnel strategic marketing.
advisors + venture partners
Ronald DePinho, M.D., is a distinguished Professor in the Department of Cancer Biology and Genomic Medicine at The University of Texas MD Anderson Cancer Center. With an MD from Albert Einstein College of Medicine, he has held numerous academic and administrative roles, including Professor at Harvard Medical School and Past President of MD Anderson. Dr. DePinho is recognized for his leadership and scientific contributions to cancer research, focusing on areas like telomere dysfunction and tumor suppression. His extensive work also includes founding initiatives like Unite to Prevent Cancer.
Dr. Manu Sebastian, PhD, is a Professor in the Department of Translational Molecular Pathology at The University of Texas MD Anderson Cancer Center. He is board-certified by prestigious organizations including the American Board of Toxicology, and also holds a DVM in Veterinary Pathology. His significant contributions to research, particularly in cancer and toxicology, are highlighted by his numerous peer-reviewed publications and substantial grant funding within the field of translational molecular pathology.